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Abstract
Mesenchymal stem cells (MSCs) are progenitors of connective tissues, which 
have emerged as important tools for tissue engineering owing to their differentia-
tion potential in various cell types. The therapeutic utility of MSCs hinges upon 
our understanding of the molecular mechanisms involved in cellular fate decisions. 
Thus, the elucidation of the regulation of MSC differentiation has attracted increas-
ing attention in recent years. A variety of external cues contribute to the process of 
MSC differentiation, including chemical, physical, and biological factors. Among 
the multiple factors that are known to affect cell fate decisions, the epigenetic 
regulation of MSC differentiation has become a research hotspot. In this chapter, we 
summarize recent progress in the determination of the effects of epigenetic modifi-
cation on the multilineage differentiation of MSCs.
Keywords: mesenchymal stromal cells, post-translational modifications, 
differentiation, cellular fate decision, epigenetic regulation
1. Introduction
Mesenchymal stromal cells (MSCs) are progenitors of connective tissues, 
initially characterized as plastic adherent, fibroblastic cells, with the potential to 
differentiate into many types of cells, including predominantly osteoblasts (cells 
that secrete the matrix of the bones), chondrocytes (cells embedded in the lacunae 
of the cartilage matrix), and adipocytes (fat-storing cells), under appropriate con-
ditions. MSC studies have progressed rapidly since the initial report of human MSC 
isolation from bone marrow. MSCs have been shown to reside within the connective 
tissues of most organs. Owing to their ease of isolation and unique characteristics, 
MSCs have been widely regarded as potential candidates for tissue engineering and 
repair. Further, the fate decision of MSCs has also piqued the interest of scientists. 
During the last two decades, various signaling molecules important to MSC differ-
entiation have been identified, and the epigenetic regulation of MSC differentiation 
has recently become a research hotspot.
The transformation process of MSCs from a self-renewing state to a specific 
lineage is always accompanied by changes in cell morphology and function, which 
are largely determined by the differential expression of genes. Specifically, genes 
related to self-renewal are turned off, and transcription of cell type-specific genes 
is activated. Epigenetic regulation refers to the phenotypic change through gene 
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differential expression without DNA sequence alteration, including four main cat-
egories: [1] DNA methylation, [2] histone modifications, and [3] chromatin remod-
eling (nucleosome positioning); and [4] non-coding RNAs. It has been widely 
reported that epigenetic and post-translational modifications have a broad and 
far-reaching influence on MSC differentiation at multiple levels. Here, we provide 
an overview of the recent findings regarding the roles of epigenetic modification in 
the fate decision of MSCs.
2. DNA methylation
DNA methylation is an important epigenetic modification referring to the addi-
tion of a methyl (-CH3) group to the fifth carbon atom of a cytosine ring to form 
5-methylcytosine (5-mC). The process is catalyzed by enzymes known as DNA 
methyltransferases (DNMTs). DNA methylation was the first epigenetic mark to be 
discovered, and it plays an important role in normal human growth, development, 
aging, tumorigenesis, and other genetic and epigenetic diseases. This epigenetic 
mark has the ability to turn genes on or off and can be inherited through cell divi-
sion. Recent studies have suggested that methylation and demethylation of specific 
genes, such as Runx2, osteopontin (Opn), distal-Less homeobox 5 (Dlx5), osterix, 
collagen type 2 (Col2), and Col10, play key roles in the multi-lineage differentiation 
of MSCs.
2.1 Osteogenic differentiation of MSCs and DNA methylation
According to numerous studies, DNA methylation is dynamically involved in the 
osteogenesis of MSCs. Generally, it may be considered that DNA methylation has 
a repressor role in the promoter regions with CpG islands, blocking gene expres-
sion. During osteogenic differentiation, demethylation was observed at specific 
CpG regions in the promoters of osteogenic lineage-specific genes, such as RUNX2, 
DLX5, SP7, SPP1 OPN, COX2, alkaline phosphatase (ALP), and osteocalcin (OCN), 
and the expression of these genes was sequentially increased, whereas the expres-
sion of pluripotent genes and hypermethylated promoters was downregulated.
Villagra et al. observed a significant hypermethylation at the osteocalcin gene 
locus in undifferentiated MSCs, and the CpG methylation of the osteocalcin pro-
moter significantly decreased upon osteogenesis induction [1]. Dansranjavin et al. 
reported that the differentiation of MSCs was accompanied by a reduced expression 
of stemness genes such as LIN28, via the hypermethylation of their promoter regions 
[2]. Arnsdorf et al. reported a protocol to promote MSC osteogenic differentiation by 
applying a mechanical stimulus [3]. According to their results, mechanical stimula-
tion causes the release of Dnmt3b from bone-specific genes, thus leading to promoter 
demethylation and upregulated gene expression. Yang et al. found that the depletion 
of demethylase Tet1 and Tet2 may hinder the demethylation of the P2rX7 promoter, 
resulting in a decrease in the osteogenic differentiation capacity of MSCs [4]. 
Furthermore, the involvement of DNA methylation in the osteogenic differentiation 
of MSCs has been supported by differentiation studies using demethylating agents. 
For example, Zhou et al. reported that pretreatment with 5-aza-2′-deoxycytidine 
(5-ADC) drives the osteogenic differentiation of MSCs by enhancing the expression 
of osteogenic genes (such as Dlx5) associated with the demethylation of the CpG 
shore [5]. Abnormal changes in the methylation modification mechanism in osteo-
genic differentiation are associated with the occurrence and development of many 
common skeletal diseases. García-Ibarbia et al. analyzed hip fracture samples from 
patients with osteoporosis and found that the activity of the Wnt signaling pathway 
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in osteoblasts was reduced. The methylation statuses of Fzd10, Tbl1x, Csnk1e, Wnt8A, 
Csnk1a1l, and Sfrp4 were also observed to be significantly different from those found 
in normal bone tissues [6]. Another study explored the differences in gene-wide 
DNA methylation patterns in osteoporosis and osteoarthritis. The results showed 
that there was a total of 241 Cpg sites with significant differences in the methylation 
status. Bioinformatic analysis showed that the sites of difference were mostly related 
to cell osteogenic differentiation and skeletal embryonic development, especially the 
homeobox family genes [7]. Sun et al. reported that abnormal CpG island hyper-
methylation of the ABCB1 gene promoter was correlated with glucocorticoid (GC)-
associated osteonecrosis of the femoral head (ONFH) in patients [8].
2.2 Adipogenic differentiation of MSCs and DNA methylation
Adipogenesis is highly regulated by a sequential cascade of transcriptional 
events. Key transcriptional factors controlling adipogenesis include several 
CCAAT/enhancer-binding protein (C/EBP) family members, including C/EBPα, 
β, and δ, and the nuclear receptor peroxisome proliferator γ (PPARγ). On the 
other hand, a number of negative transcriptional factors have also been identified, 
including GATA2/3, chicken ovalbumin upstream promoter transcription factor 
(COUP-TF), interferon regulatory factors (IRFs), and Wnt family proteins.
Barrand et al. showed that the promoters of stemness genes (OCT4, NANOG, and 
SOX2) were hypermethylated in adipose-derived MSCs [9]. In addition, the promot-
ers of adipogenic genes, including leptin (LEP), PPARγ2, fatty acid-binding protein 4 
(FABP4), and lipoprotein lipase (LPL), are hypomethylated in these undifferentiated 
MSCs, as revealed by Noer et al [10]. It was reported by Fujiki et al. and Melzner et al. 
that the promoters of PPARγ2 and LEP were progressively demethylated along with 
the terminal differentiation of adipocytes [11, 12]. Studies also revealed that the levels 
of the DNA methyltransferase 1 (DNMT1) gene transcript increased at the beginning 
of adipogenesis and then decreased [13], while the levels of DNMT3a and DNMT3b 
transcripts increased during differentiation [14]. Wnt signaling is a key determinant 
of the fate between adipogenic and osteogenic differentiation. Chen et al. proved that 
the methylation level of the Wnt10a 5-region was markedly reduced in MSCs after 
5-Aza-dC treatment, which likely significantly inhibited adipogenesis and promoted 
osteogenesis [15].
2.3 Chondrogenic differentiation of MSCs and DNA methylation
DNA methylation and demethylation status also influence MSC chondro-
genic differentiation. DNA methylation at specific CpGs has been shown to 
influence genes such as MMP13, IL1, iNOS, chondromodulin, collagen 9, and 
GDF5 in chondrocytes. Similarly, induction of COL10A1 expression during 
chondrogenesis of MSCs is correlated with the demethylation of two CpG sites 
in the COL10A1 promoter. In addition, Kim et al. also showed an elevated extent 
of DNA methylation in the SOX9 promoter in damaged chondrocytes of osteo-
arthritis (OA) patients compared to the observation in normal chondrocytes 
[16]. More recently, Barter et al. characterized the DNA methylation changes 
during the chondrogenesis of MSCs using an Infinium 450 K methylation array. 
A chondrocyte-specific methylation profile was established by comparison with 
cartilage and non-cartilage tissue methylation profiles, and they also identified 
significant changes in DNA hypomethylation at many key cartilage gene loci 
during chondrogenic differentiation, including COL11A2, SOX9, and ACAN 
[17]. Further studies analyzing these epigenetic changes during chondrogenesis 
are needed.
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3. Histone epigenetic modification
Histone modification, a common form of epigenetic regulation, refers to 
post-translational modifications that are added to the N-terminal tail of histones. 
Histone modification has been shown to play important roles in regulating cell-
specific gene expression. So far, more than sixty different residues on core histones 
(H2A, H2B, H3, H4) with potential to be modified have been reported. These 
modifications made to histones, including acylation, methylation, phosphoryla-
tion, ubiquitination, and sumoylation, can impact gene expression by altering the 
chromatin structure or recruiting histone modifiers. Histone proteins function 
to package DNA, which wraps around the eight histones, into chromosomes. In 
general, it has been well established that histones on the promoter regions of 
master transcription factors associated with MSC cell fate commitment, such as 
RUNX2 and OSX in osteogenic differentiation, PPARG and CEBPA in adipogenic 
differentiation and SOX9 in chondrogenic differentiation, are dynamically modi-
fied (Table 1). In response to appropriate developmental and/or differentiation 
signals, histone modifications act in diverse biological processes such as transcrip-
tional activation/inactivation, chromosome packaging, and DNA damage/repair. 
Furthermore, different types of modifications may have synergistic or antagonistic 
effects to regulate specific gene expression.
3.1 Histone acetylation modification
Histone acetylation is an epigenetic modification characterized by the addi-
tion of an acetyl group (COCH3) to histone proteins, specifically to lysine residues 
within the N-terminal tail. Histone acetylation is one of the most common epigen-
etic modifications, which leads to the neutralization of the positive charge on the 
histone proteins, weakening their interaction with DNA, and finally promoting the 
opening of chromatin structure and activating gene transcription. On the other 
hand, histone deacetylation is related to chromatin transcription inhibition. The 
level of histone acetylation is mainly regulated by histone acetylase (HAT) and 
histone deacetylase (HDAC).
The degree of histone acetylation of related regulatory genes can reflect the 
maintenance of stemness and the differentiation status of MSCs. During the process 
of osteogenic differentiation, the expression of osteogenic genes (such as RUNX2, 
OSX, and ALP) gradually increases in MSCs, while the expression of stemness-
related genes (such as OCT4 and SOX2) is significantly decreased. These changes 
in gene expression were found to be closely related to H3K9Ac and H3K14Ac, which 
can be used as marks of gene activation. The regulatory roles of histone acetylases in 
osteoblast differentiation have been increasingly recognized. According to previous 
and existing studies, HDAC1, HDAC6, HDAC8, and SIRT1 play important roles 
in the differentiation of MSCs. For example, Wang et al. found that inhibiting the 
expression of histone deacetylase 1 (HDAC1) can effectively enhance the osteogenic 
differentiation, gene expression, and the bone formation activity of bone mar-
row MSCs under mechanical stimulation [25]. Lu et al. showed that HDAC1 has a 
negative correlation with cardiac cell differentiation of MSCs under a myocardial 
microenvironment. During this process, the expression of HDAC1 in MSCs was 
significantly decreased in a time-dependent manner. In addition, their data proved 
that the knockdown of HDAC1 promoted the directed differentiation of MSCs 
into cardiac cells [26]. Several studies have shown that the expression of HDAC6 
is reduced during osteogenic differentiation, and HDAC6 negatively regulates the 
expression of OC, osteopontin (OPN), BSP2, OSX, and ALP partly by binding to 
the RUNX2 C-terminus and adjusting RUNX2 activity [27–29]. Fu et al. reported 
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that the pharmacological inhibition of HDAC8 by the HDAC inhibitor, valproic acid 
(VPA), increased the levels of H3K9Ac and significantly enhanced the expression 
of the osteogenesis-related genes RUNX2, osterix, OCN, OPN, and ALP. Similarly, 
knockdown of HDAC8 enhanced the osteogenic differentiation of MSCs [30]. 
Furthermore, SIRT1, an NAD + -dependent deacetylase, also acts as a key regula-
tor of MSC differentiation. The decrease in its activity reduces the expression of 
the stemness factor Sox2, which leads to the degradation of the self-renewal and 
differentiation ability of MSCs [31]. It was reported that SIRT1 knock-out MSCs 
showed reduced differentiation toward osteoblasts and chondrocytes in vitro, 
but showed no difference in proliferation or apoptosis. Petra et al. showed that 
SIRT1 deacetylates β-catenin to promote its accumulation in the nucleus, leading 
to the transcription of genes for MSC differentiation [21]. Additionally, epigenetic 
research has shed light on the effects of histone acetylation on adipogenesis and 
chondrogenesis. Chemically distinct HDAC inhibitors have been shown to prevent 
adipocyte differentiation [32]. It has been reported that SIRT2 acts as an important 
regulator of adipocyte differentiation through the deacetylation of forkhead box 
protein O1 (FOXO1), peroxisome proliferator-activated receptor gamma (PPARγ), 
and CCAAT/enhancer binding protein β (C/EBPβ) [33, 34]. Nakade et al. showed 
that Jun dimerization protein 2 (JDP2) plays a key role as a repressor of adipocyte 
differentiation by regulating the expression of C/EBPδ via the inhibition of histone 
acetylation [35]. In addition, SIRT1 can also promote the cartilage differentiation 
process of MSCs by activating the deacetylation of Sox9 and NF-κB [36].
3.2 Histone methylation
Histone methylation is another common post-translational modification by 
which methyl groups are transferred to the amino acids of histone proteins that 
make up the nucleosomes. Histone methylation can occur at various sites in histone 
proteins, primarily on lysine and arginine residues, and it can be governed by 
multiple positive and negative regulators, even at a single site, to either activate or 
repress transcription. Histone methylation is regulated by histone methyltrans-
ferase (HMT) and histone demethylase (HDM), which can be monomethylated, 
dimethylated, or trimethylated.
The increase in methylation usually promotes the affinity of histones to DNA 
and increases the degree of transcriptional inhibition, such as H3K9 methyla-
tion and H3K27 methylation. H3K9 dimethylation and trimethylation are typical 
repressive histone modifications that mediate the formation of heterochromatic 
regions. It was reported that the knockdown of ESET, a H3K9 methyltransferase, 
causes an aberrant expression of Runx2 and finally leads to the impairment 
of osteogenic differentiation and bone defects in mice. On the other hand, the 
knockdown of EHMT1, a H3K9 specific methyltransferase, resulted in decreased 
H3K9me2 levels on the promoters of Runx2, thereby upregulating transcription 
in mouse tissues. With respect to the adipogenic differentiation of MSCs, it was 
found that the enrichment of H3K9me1 and H3K9me2 on the promoters of C/EBP 
and PPARγ was negatively associated with adipogenic differentiation. Lowering 
the H3K9 methylation levels in these regions by either H3K9 demethylase or HMT 
inhibitors ultimately promoted adipogenic differentiation. In addition, H3K9me3 
levels in the promoter region of Sox9, as well as its target genes Col2a1 and aggre-
can, were found to be negatively correlated with the chondrogenic differentiation 
of MSCs. H3K27 methylation is another heterochromatic histone modification 
associated with transcriptional repression. H3K27me3 on the promoters of Wnt 
family genes, including Wnt1, Wnt6, Wnt10a, and Wnt10b, was increased dur-
ing osteogenesis. Knockdown of the H3K27me3 demethylases such as KDM4B 
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and KDM6B attenuated osteogenesis. Moreover, H3K27me3 demethylases have 
also been reported to facilitate the adipogenic and chondrogenic differentiation 
of MSCs. Hemming et al. found that high expression of the enhancer of zeste 
homolog 2 (EZH2), a histone methyltransferase catalyzes the tri-methylation of 
chromatin H3K27, promotes the adipogenic differentiation of MSCs, and inhibits 
the osteogenic differentiation, while demethylase KDM6A has the opposite effect. 
In contrast to H3K9 and H3K27 methylation, methylation of H3K4 is associated 
with an active transcription state. It has been reported that H3K4me3 levels are 
negatively associated with osteogenesis. HDMs, such as KDM5A and KDM5B, 
which specifically demethylate H3K4, were found to influence MSC osteogenic 
differentiation. A recent study also reported that silencing of Ash1l, an H3K4 
methyltransferase, promotes adipogenesis while suppressing osteogenesis and 
chondrogenesis (Figure 1).
4. Chromatin remodeling
Chromatin remodeling is the dynamic modification of chromatin architecture, 
which is an important mechanism for regulating gene expression. In eukaryotes, 
DNA is tightly wound into a complex called chromatin. Chromatin remodeling 
allows the access of tightly condensed DNA to various regulatory factors, such as 
transcription factors and components of DNA replication, so that specific genes can 
be expressed. The basic mechanism of chromatin remodeling depends on the three 
Figure 1. 
The mechanisms of histones modification.
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dynamic properties of nucleosomes: reconstruction, enzyme-induced covalent 
modification, and repositioning. In addition, the aforementioned histone modifica-
tion is another important aspect of chromatin remodeling. Aberrations in chroma-
tin remodeling proteins are associated with various human disorders and diseases. 
The major activities involved in nucleosome structure alterations use the energy 
supplied by ATP hydrolysis to affect nucleosomes. These enzymes are called ATP-
dependent chromatin (or nucleosome) remodeling factors. The system involves four 
subfamilies of ATP-dependent chromatin remodeling complexes, namely switch/
sucrose non-fermentable (SWI/SNF), nucleosome remodeler deacetylase (NuRD), 
INO80, and imitation switch (ISWI).
Several studies have demonstrated that functional SWI/SNF machinery plays 
an important role in regulating MSC tri-lineage differentiation by interacting with 
tissue-specific transcription factors and crosstalk with cell signaling pathways. 
Brahma-associated factor (BAF) complex subunits have been implicated in MSC 
osteo-lineage commitment. For example, depletion of BRG1 leads to constitutive 
osteo-lineage gene expression [37]. BRM negatively regulates osteocalcin expression 
[38]. Loss of the classical BAF restricted subunit Pbrm1/Arid2/Brd7 leads to reduced 
osteogenesis without compromising adipogenesis [39]. It has also been reported 
that SWI/SNF-dependent chromatin remodeling is involved in MSC adipogenic 
differentiation. BRG1 overexpression was associated with promoted adipogenic 
differentiation, which was associated with a marked increase in the differentiation 
markers PPARγ and LPL [40]. BAF45A was identified as an important regulator of 
adipogenic differentiation in human MSCs [41]. In addition, other ATP-dependent 
chromatin remodelers, such as chromodomain helicase DNA binding (CHD) 
proteins, are also involved in MSC lineage commitment. CHD4 was reported to be 
implicated in chondrogenesis. Simon et al. reported that CHD1 is required for the 
induction of osteoblast-specific gene expression, extracellular-matrix mineraliza-
tion, and ectopic bone formation in vivo [42]. CReMM plays a role in mediating the 
transcriptional response to hormones that coordinate osteoblast function [42, 43]. 
It was proved by Kumar et al. that metastasis-associated gene 1(MTA1) negatively 
regulates osteo-lineage gene expression [44]. Together, chromatin remodeling plays 
an important role in MSC lineage commitment.
5. Non-coding RNAs
The RNA world is divided into two classes: 1) RNAs that have coding potential 
(mRNAs) and 2) RNAs without coding potential, referred to as non-coding RNAs 
(ncRNAs). Although mRNAs have been extensively studied, ncRNAs span more 
than 98% of DNA transcripts. In the past, these molecules were considered as “evo-
lutionary junk” but increasing evidence suggests that these molecules spatiotem-
porally regulate protein-coding gene expression in several molecular mechanisms. 
With improved RNA-sequencing techniques, in recent years, there have been great 
advances in identifying and understanding ncRNAs. Epigenetic ncRNAs, including 
microRNAs (miRNAs), small interfering RNAs (siRNAs), piwi-interacting RNA 
(piRNA), and long noncoding RNAs (lncRNA), have been reported to play key roles 
in the regulation of various diseases and biological processes, including cellular 
differentiation, proliferation, apoptosis, gene regulation, and cancer development.
5.1 Long non-coding RNA
lncRNA is a novel class of noncoding RNAs longer than 200 nt, which can regu-
late gene expression at the transcriptional and post-transcriptional levels. LncRNAs 
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are mainly located in the cell nucleus or cytoplasm, affecting the status and fate of 
cells through different post-transcriptional mechanisms. Nuclear lncRNAs guide 
chromatin modifiers, such as DNA methyltransferase, histone methyltransferase, 
and heteronuclear ribosome protein, to a specific genetic locus and induce chroma-
tin structure remodeling, which in turn regulates gene expression either positively 
or negatively. Cytoplasmic lncRNAs can either block the functional site or alter the 
structure and modification of specific proteins, thereby regulating the function 
and stabilization of these proteins, and ultimately alter the fate and function of 
cells. During the last decade, multiple studies have demonstrated that lncRNAs are 
widely involved in growth and development by controlling the fate of cells, includ-
ing MSCs.
Studies have demonstrated the importance of lncRNAs in bone regeneration and 
bone formation. Many lncRNAs regulating the osteogenic differentiation of MSCs 
have been identified, including ANCR, AK141205, AK028326, DANCR, MALAT1, 
MEG3, MORD, and POIR; these either promote or inhibit osteogenic differentiation 
through diverse pathways. For example, MALAT1 promotes OSX expression and the 
osteogenesis of MSCs by sponging miR-143, and MALAT1 can be used as a biomarker 
for the detection of osteoporosis [45]. MEG3 inhibited bone morphogenetic protein 
2 (BMP2) through interaction with hnRNPI, which plays an active role in mRNA 
splicing, and finally suppresses osteogenic differentiation [46]. Exosome-transferred 
lncRNA, RUNX2 antisense RNA 1 (RUNX2-AS1), decreases the expression of 
RUNX2 in MSCs by forming an RNA duplex with RUNX2, consequently suppressing 
osteogenesis [47]. MEG3 has also been shown to promote osteogenic differentiation 
in MSCs via the BMP4 signaling pathway [48]. Moreover, lncRNAs are associated 
with osteogenesis through the regulation of classical signaling pathways, including 
the Wnt/β-catenin pathway, p38 mitogen-activated protein kinase (MAPK) path-
way, Notch signaling pathway, and nuclear factor-κB (NFκB) signaling pathway. 
Currently, few studies have focused on lncRNA expression and their functions in 
the chondrogenic and adipogenic differentiation of MSCs. Xiao et al. reported that 
adipogenic differentiation-induced noncoding RNA (ADINR) was significantly 
upregulated in MSCs after adipogenic induction. Knocking out ADINR significantly 
inhibited the ability of MSCs to differentiate into adipocytes. A mechanistic study 
revealed that ADINR positively regulates the expression of the transcription factor 
C/EBPα [49]. Wang et al. reported that the expression of the lncRNAs ZBED3-AS1 
and CTA-941F9.9 was significantly upregulated during the differentiation process of 
MSCs toward cartilage [50].
5.2 MicroRNA
MicroRNAs are the most abundant class of small ncRNAs with a length of 
21–25 nt, and have been studied extensively. miRNAs are also involved in the 
epigenetic regulation of genes in both the cytoplasm and nucleus through different 
mechanisms. Their main action is the negative regulation of gene expression by 
specifically binding to a target mRNA through base complementary pairing and 
inducing its degradation or the inhibition of its translation.
Accumulating evidence indicates that miRNAs play an important role in the 
maintenance of stemness and differentiation of MSCs (Table 2). As mentioned 
above, lineage differentiation of MSCs is a complex biological process. For example, 
MSCs differentiate into osteogenic progenitor cells and subsequently osteoblasts, 
and then gradually become mature bone cells along with a variety of extracel-
lular matrix mineralization. This process involves a large number of secretory and 
transcription factors. In addition, the differentiation and maturation of MSCs also 
involves signaling pathways such as WNT, BMP, and PI3K/Akt. The key effector 
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molecules in these pathways can be regulated by miRNAs, which in turn affects 
MSC fate decisions. Recently, various miRNAs, including miR-20b, -29b, -30a-5p, 
-142-3p, -196a, -210, -746-5p, -2861, -3960, -335-5p, etc., have been reported to 
enhance osteogenic differentiation, whereas miR -23a, -26a, -30c, -34b, -34c, 
-125, -133a, -135a, -137, -141, -148, -200a, -204, -205, -206, -217, and -338 could 
impede osteogenic differentiation, and miR-143, -24, -31, -30c, and -642a-3p are 
involved in regulating adipogenesis. Oskowitz et al. reported that silencing of Dicer 
or Drosha, two key enzymes in the miRNA biogenesis pathway, inhibits both the 




miR-23a targets LRP5 and subsequently suppress 
the Wnt/β-catenin signaling pathway
Inhibit osteogenesis of MSCs [51]
miR-26a in BMSCs: targets GSK3β mainly and 
activates Wnt/β-catenin signaling 
pathway;
in ADSCs: targets Smad1 mainly and 
inhibits BMP signaling pathway
Inhibit osteogenesis of 
ADSCs and promote 
osteogenesis of BMSCs
[52]









miR-20b Activate the BMPs/Runx2 signaling 
pathway at four levels, which consists of 
repressing PPARγ, Bambi and Crim1
Promote ostegenesis [54, 55]
miR-29b activates the AKT/β-catenin signaling 
pathway by inhibiting PTEN expression
Promote osteogenesis of 
hADSCs
[56]
miR-196a targets HOXC8 (a negative regulator
of SMAD1)
Inhibit proliferation and 
promote osteogenesis of 
hDASCs
[57]
miR-17-5p Represses the Wnt signaling pathway 
effector Tcf7l2
Promote adipogenesis of 
BM-MSCs
[58, 59]
miR-21 Alters SMAD3 phosphorylation without 
affecting total levels of SMAD3 protein 
and modulate TGF-β signaling pathway
[59, 60]
miR-143 Directly represses MAP2K5 (a key 
member of the MAPKK family in the 
MAPK signaling pathway)
[59, 61]








miRNA and MSCs differentiation.
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reported to act as switches for MSCs to differentiate into different lineages. For 
example, the miR-17 cluster of the miRNA family, miR-17-5p, miR-106a, and miR-
20a, are downregulated when the cell undergoes osteogenic differentiation and is 
upregulated during adipocyte differentiation [64]. Miyaki et al. also demonstrated 
that the expression of miR-140 increased during chondrocytic differentiation 
along with the expression of Sox9, Aggercan, and Col2A1 [65]. In addition, recent 
research has found that miRNAs can form a competitive endogenous RNA regula-
tion network with lncRNAs and circRNAs. Some research groups have started 
paying more attention to this regulatory network, which will further improve our 
understanding of the role of ncRNAs in MSC maintenance and differentiation.
6. Conclusions
“Epigenetics” was first used to define the complex interactions between the 
genome and the environment that are involved in the development and differen-
tiation of organisms. Nowadays, the term refers to heritable alterations in gene 
expression that are not mediated at the DNA sequence level. Accumulating evidence 
has suggested that the processes of epigenetic modifications are crucial and largely 
responsible for the variable activation and repression of specific genes at specific 
time points during the lifespan of stem cells, allowing for the terminally differenti-
ated phenotype. With the advances in biological and experimental technologies, 
a variety of epigenetic modifications involved in the cell fate determination of 
MSCs have been discovered in recent years. In addition to the types of epigenetic 
modifications introduced in the article, some researchers have suggested the role of 
histone phosphorylation, ubiquitination, and other modifications in the differen-
tiation of MSCs. On this basis this information, drugs that effectively regulate these 
modifications have been developed to provide precise differentiation conditions 
for MSCs and make them more effective in clinical treatment. The disadvantage of 
epigenetic therapy using small molecule drugs is the lack of specificity, which needs 
to be further studied. In summary, epigenetic modifications play an important 
regulatory role in the cell fate determination of MSCs, but the precise function of 
these modifications in different MSC types, as well as the associated underlying 
mechanisms, remain to be thoroughly investigated. In-depth research in this field 
would provide important reference data for the differentiation mechanism research 
and clinical application of MSCs.
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